Medical device distribution in Saudi Arabia: A strategic rethink for global companies
Global medical device companies may need to strategically revisit how much of their Saudi business they delegate to local distributors as well as their local operating models, according to a new whitepaper from Eurogroup Consulting.
The traditional approach for medical device companies seeking a presence and growth in Saudi Arabia was straightforward: appoint a distributor, complete registration, participate in tenders and support key accounts from a regional office. The whitepaper from the international management consulting firm asserts that this model still works in certain cases – but it has its limitations in high-value, service-intensive and strategically important categories.
The authors shed light on how procurement complexity, service expectations and local-content requirements are changing competition, and argue that companies seeking growth increasingly need a dedicated Saudi operating model – with clear roles for manufacturers, local teams and partners – aligned with the direction of Vision 2030.
They also highlight the complexity that comes with local distribution. For example, some purchasing decisions may involve clinicians, biomedical engineering teams, procurement and finance functions, hospital clusters and centralized channels such as NUPCO. LCGPA-related local-content considerations add another layer to market access and competitiveness.
Saudi healthcare buyers also increasingly expect suppliers to show how their technologies improve workflows and capacity, support clinical training and adoption, provide reliable after-sales service, integrate with existing systems, and deliver measurable clinical or economic value – raising the importance of local account management, clinical education and technical support.
These developments are changing the playbook. “The old playbook for medical device companies is no longer fit for purpose in the current market environment,” said Jack Fowler, Principal at Eurogroup Consulting.
“Saudi healthcare decisions are no longer won through one relationship or one tender. They are shaped across clinical, technical, procurement and financial priorities. Local partners remain essential, but without direct visibility into strategic accounts, service standards and market data, manufacturers risk losing influence where growth is decided.”
As a result, manufacturers need greater control over strategic accounts, tenders, service quality, data and local-content planning, while continuing to rely on Saudi partners for execution and reach.
The distributor model
A key question to be resolved in the Saudi market is what parts of the value chain should be ‘owned’. The whitepaper sets out a five-model distributor spectrum – from a Traditional Distributor-Led Model to a Strategic Localization Partner Model, with the right structure depending on scale, portfolio and localization goals.
A fully direct model for instance offers greater control but brings higher costs and execution risk, while a purely distributor-led model can limit visibility and influence over strategic accounts.
“Distributors remain important links to Saudi healthcare providers, but their role is moving from broad market ownership toward execution under clearer governance, targets and reporting,” said Fowler.
Localization
The Local Content and Government Procurement Authority (LCGPA) has become an important part of the Saudi business environment. Its role is to increase local content in government procurement and encourage companies to contribute more to the domestic economy.
For medical device companies, this creates a shift in how competitiveness is assessed. Public-sector buyers and procurement stakeholders are increasingly interested in whether suppliers contribute to the Kingdom beyond importing products.
“The strategic implication is clear: local content is becoming more relevant to market access and procurement. And companies that can show credible local contribution may be better positioned than companies that remain purely import-driven,” noted Fowler. “But localization does not automatically require manufacturing in Saudi Arabia.”
Through a five-phase roadmap, the authors guide leaders of medical device groups through the strategic decision on how to deal with localization, including the option of establishing a Regional Headquarters in the Kingdom.
